Today: 10 June 2026
Browse Category

NYSE:NVO 6 January 2026 - 23 January 2026

Novo Nordisk stock price jumps before the bell as Wegovy pill prescriptions leap

Novo Nordisk stock price jumps before the bell as Wegovy pill prescriptions leap

Novo Nordisk shares rose 4.9% to $62.23 in premarket trading after new data showed U.S. prescriptions for the oral Wegovy pill jumped to 20,392 from 4,286. The surge comes as investors watch prescription trends ahead of Novo’s Feb. 4 results. Rival Eli Lilly shares edged up 0.8%. India’s Sun Pharmaceutical won approval to produce generic semaglutide after the patent expires in March.
23 January 2026
·
Novo Nordisk stock jumps on Wegovy pill prescriptions — what investors watch next week

Novo Nordisk stock jumps on Wegovy pill prescriptions — what investors watch next week

Novo Nordisk shares surged 6.49% to 388.90 Danish crowns Friday after early U.S. prescription data for its new Wegovy pill and UK approval of a higher Wegovy dose. U.S. retail pharmacies filled 3,071 Wegovy pill prescriptions in the first four days, not counting online sales. Novo’s ADRs rose 0.74% in New York. Investors await the company’s earnings report on Feb. 4.
18 January 2026
·
Novo Nordisk stock jumps on Wegovy pill scripts and UK high-dose nod — what to watch next week

Novo Nordisk stock jumps on Wegovy pill scripts and UK high-dose nod — what to watch next week

Novo Nordisk shares surged 6.5% in Copenhagen and 9.1% in New York after early U.S. prescription data showed 3,071 Wegovy pill scripts filled in four days. Britain approved a higher maximum dose of Wegovy for obesity patients. A Texas compounding pharmacy sued Novo and Eli Lilly over alleged market dominance. Novo called the lawsuit “without merit.”
17 January 2026
···
Pfizer stock dips as U.S. vaccine policy fight rattles demand outlook

Pfizer stock dips as U.S. vaccine policy fight rattles demand outlook

Pfizer shares fell 0.6% to $25.42 in late-morning trading Thursday as U.S. vaccine policy changes fueled uncertainty. Sanofi warned of weaker U.S. vaccine demand; Pfizer’s CEO criticized the new recommendations. Moderna and Merck also traded lower. Investors await Pfizer’s Feb. 3 results for updates on 2026 outlook and new product pipeline.
15 January 2026
········
Structure Therapeutics stock jumps as Novo deal talk lifts obesity-drug names

Structure Therapeutics stock jumps as Novo deal talk lifts obesity-drug names

Structure Therapeutics (GPCR) shares surged 7.5% to $83.76 Wednesday on over 1 million shares traded, fueled by buyout speculation and renewed interest in oral obesity drugs. Novo Nordisk executives signaled openness to acquisitions, while Structure reported Phase 2b data showing its oral GLP-1 drug aleniglipron led to 11.3% placebo-adjusted weight loss at 36 weeks. Viking Therapeutics and Terns Pharmaceuticals also rose sharply.
14 January 2026
······
Pfizer stock rises as CEO likens obesity-drug boom to Viagra ahead of Feb. 3 earnings

Pfizer stock rises as CEO likens obesity-drug boom to Viagra ahead of Feb. 3 earnings

Pfizer shares rose 1.4% to $25.51 Wednesday morning, outpacing a broader market decline. CEO Albert Bourla said the company misjudged the cash-pay obesity drug market and plans about 10 Phase 3 obesity trials in 2026. Investors are watching for Feb. 3 results and updates on late-stage trial launches. Pfizer expects no revenue growth before 2029 as it faces major patent expirations.
14 January 2026
·····
Pfizer stock slips as CEO says obesity cash-pay market is “almost like Viagra”

Pfizer stock slips as CEO says obesity cash-pay market is “almost like Viagra”

Pfizer shares fell 0.7% to $25.10 Tuesday after CEO Albert Bourla told the J.P. Morgan Healthcare Conference the cash-pay obesity market is larger than expected. Pfizer plans 10 phase 3 trials for its Metsera drugs by end-2026 but does not expect revenue growth until 2029. Investors await Feb. 3 results for updates on the obesity pipeline and 2026 strategy. Rival Novo Nordisk launched a daily oral Wegovy in the U.S. this month.
13 January 2026
····
Pfizer stock dips as CEO says obesity-drug cash-pay demand looks “almost like Viagra”

Pfizer stock dips as CEO says obesity-drug cash-pay demand looks “almost like Viagra”

Pfizer shares fell 0.8% to $25.27 after CEO Albert Bourla compared the obesity drug cash-pay market to Viagra’s early days. The company, which acquired Metsera for up to $10 billion, aims to start up to 10 Phase 3 trials for Metsera’s GLP-1 drug by end-2026. Eli Lilly and Novo Nordisk shares rose, while Pfizer trails rivals in the obesity market.
13 January 2026
···
Novo Nordisk stock: Amazon starts selling Wegovy pill, putting next week in focus

Novo Nordisk stock: Amazon starts selling Wegovy pill, putting next week in focus

Novo Nordisk shares rose 3% in Copenhagen on Friday after Amazon Pharmacy began offering the Wegovy weight-loss pill with insurance and cash-pay options. U.S.-listed ADRs gained 2.6%. Amazon set insured prices as low as $25 per month, with cash prices starting at $149. Investors are watching CEO Mike Doustdar’s upcoming appearance at the J.P. Morgan Healthcare Conference.
11 January 2026
···
Eli Lilly stock (LLY) slips into JPM Week as Amazon adds rival Wegovy pill — what to watch next

Eli Lilly stock (LLY) slips into JPM Week as Amazon adds rival Wegovy pill — what to watch next

Eli Lilly shares fell 1.99% to $1,063.56 Friday, trailing a record-setting S&P 500. Amazon Pharmacy began selling Novo Nordisk’s Wegovy pill for $149 a month, raising concerns about pricing pressure in obesity drugs. Lilly is set to address investors at the J.P. Morgan Healthcare Conference on Tuesday.
11 January 2026
······
Amazon Pharmacy adds Wegovy pill at $149 cash price, putting Novo Nordisk’s NVO stock back in play

Amazon Pharmacy adds Wegovy pill at $149 cash price, putting Novo Nordisk’s NVO stock back in play

Amazon Pharmacy will offer Novo Nordisk’s Wegovy weight-loss pill through insurance and cash-pay, with uninsured customers paying from $149 a month and some insured paying $25. The pill, approved by the FDA in December, will be added to Amazon’s kiosks and is also available at CVS, Costco, and via telehealth. Novo’s U.S. shares rose about 5% to $60.19 Friday morning. Analysts remain split on Novo’s 2026 outlook.
9 January 2026
···
Amazon stock dips as Amazon Pharmacy adds Novo Nordisk’s Wegovy pill, with $25 insured pricing

Amazon stock dips as Amazon Pharmacy adds Novo Nordisk’s Wegovy pill, with $25 insured pricing

Amazon Pharmacy began offering Novo Nordisk’s Wegovy pill nationwide, with insured customers paying as little as $25 per month and uninsured starting at $149. The oral weight-loss drug, approved by U.S. regulators in December, is available for delivery in all 50 states. Amazon shares fell 0.7% to $244.58 in early trading. Broader markets were little changed.
9 January 2026
···
Novo Nordisk (NVO) stock rises premarket as Canada platform touts India-sourced Ozempic

Novo Nordisk (NVO) stock rises premarket as Canada platform touts India-sourced Ozempic

Novo Nordisk’s U.S. shares rose 1.4% in premarket trading after the company denied any relationship with SaveRxCanada.to, which claims to sell India-sourced Ozempic to U.S. patients at $280 per pen. Novo said it has not supplied Ozempic to the platform. The dispute comes as drug pricing faces renewed political scrutiny and ahead of the J.P. Morgan Healthcare Conference.
9 January 2026
···
Novo Nordisk (NVO) stock jumps as $149 Wegovy pill rollout puts pricing in the spotlight

Novo Nordisk (NVO) stock jumps as $149 Wegovy pill rollout puts pricing in the spotlight

Novo Nordisk’s U.S.-listed shares rose 4.7% to $57.71 Tuesday after launching oral Wegovy for self-pay patients at $149 a month for starter doses. The pill is now available at major pharmacies and through telehealth. Investors await early demand data and updates from a key healthcare conference on Jan. 13. Rival Eli Lilly expects a regulatory decision on its own weight-loss pill in March.
6 January 2026
···
Novo Nordisk stock jumps premarket as $149 Wegovy pill hits U.S. market

Novo Nordisk stock jumps premarket as $149 Wegovy pill hits U.S. market

Novo Nordisk’s U.S.-listed shares rose about 4% in premarket trading after the company launched an oral version of its Wegovy weight-loss drug, priced from $149 a month for some cash-paying patients. The stock traded at $57.29, up from $55.11. Investors are watching early demand and await the company’s February 4 results for margin outlook. The launch comes amid restructuring and job cuts at Novo’s U.S. operations.
6 January 2026
···
1 2 3 4 5 … 7

Stock Market Today

  • Tencent Shares Rise 3.22% After $4.66 Billion Bond Sale Fuels AI Investment
    June 10, 2026, 5:05 AM EDT. Tencent Holdings Ltd shares rose 3.22% to HK$467.80 in Hong Kong following the pricing of a US$4.66 billion dual-currency bond deal, comprising US$2.45 billion in dollar notes and CNY15 billion in offshore yuan notes. The bond sale attracted over US$17 billion in orders, allowing Tencent to cut pricing across four tranches. The company plans to use proceeds for general corporate purposes, including refinancing. Investors reacted positively despite Tencent's increased spending on artificial intelligence (AI), with first-quarter capital expenditures at RMB31.94 billion and free cash flow of RMB56.7 billion. CFO John Lo highlighted Tencent's strong balance sheet as the firm balances debt issuance with AI financing needs.

Latest articles

Roche Shares Edge Up After $2.3 Billion Nurix Cancer Pact

Roche Shares Edge Up After $2.3 Billion Nurix Cancer Pact

10 June 2026
Roche’s participation certificates climbed 1.07% to CHF 322.20 after announcing a $2.3 billion deal with Nurix Therapeutics for late-stage blood-cancer drug bexobrutideg, planned to enter Phase 3 trials this summer in CLL, as investors weigh the asset’s potential to offset losses from expiring patents and drive mid-single-digit sales growth in 2026.
YY Group Shares Jump Premarket on Humanoid Robot Move

YY Group Shares Jump Premarket on Humanoid Robot Move

10 June 2026
YYGH jumped to $0.19 in early pre-market after announcing deployment of Unitree G1 humanoid robots for facility management, aiming to turn operational know-how into higher-margin data assets, but the stock remains volatile near record lows after a recent reverse split and has not confirmed robot-driven revenue or margin gains.
Tencent Shares Gain After $4.66B Bond Sale Seen Fueling AI Bets

Tencent Shares Gain After $4.66B Bond Sale Seen Fueling AI Bets

10 June 2026
Tencent shares jumped 3.22% to HK$467.80 after the company priced a larger-than-expected US$4.66 billion dual-currency bond deal, drawing over US$17 billion in orders and allowing tighter pricing, as investors weighed Tencent’s ability to fund rising AI investments while maintaining strong cash flow and ongoing share buybacks.
PAVS Stock Jumps Again, $195M Share Sale Filing in Focus

PAVS Stock Jumps Again, $195M Share Sale Filing in Focus

10 June 2026
Paranovus Entertainment Technology shares jumped 19.6% premarket after filing plans for an at-the-market share sale of up to $194.99 million—an unusually large amount compared to its $1.07 million market value—raising dilution risks as the company can sell shares at prevailing prices with no minimums, while recent trading has been highly volatile and underlying operations remain limited.
Marvell Is Now in the S&P 500. The Focus Turns to Its Next Move

Marvell Is Now in the S&P 500. The Focus Turns to Its Next Move

10 June 2026
Marvell plunged 7.6% to $266.88 after Monday’s S&P 500-driven surge, as semiconductor stocks sold off despite the chipmaker’s looming June 22 index inclusion and strong AI demand; shares had soared 59% since May 27 on bullish custom-chip forecasts, but high valuation and sector volatility now threaten further gains.
Go toTop